Teva Pharmaceutical (TEVA) Tops Q2 EPS by 2c; Boosts FY14 EPS Outlook
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (NYSE: TEVA) reported Q2 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.08 billion.
EPS guidance for 2014 improved to $4.90-5.10 in the exclusive Copaxone scenario, and to $4.50-4.80 in the generic Copaxone® scenario. The consensus is at $4.82.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
- IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!